© 2023 © 2020 Genprex Inc. All Rights Reserved.
Recommends Advancing Acclaim-1 to Increased Dose in Second Cohort of Phase 1 Portion of Trial
Genprex is harnessing the power of a combinational treatment approach to overcome treatment limitations and offer patients new treatment options.
Technology Networks spoke with Rodney Varner, CEO of Genprex, to learn more about the next steps for Oncoprex and how the FDA Fast Track Designation will facilitate the delivery of this drug to cancer patients.